株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の禁煙補助薬市場の予測 - 2017年〜2027年:NRT、非ニコチン系薬物療法、処方薬、OTC薬

Global Smoking Cessation Drugs Market Forecast 2017-2027: NRT, Non-nicotine Pharmacotherapy, Prescription Drugs, OTC Drugs

発行 Visiongain Ltd 商品コード 243886
出版日 ページ情報 英文 280 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=150.55円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
世界の禁煙補助薬市場の予測 - 2017年〜2027年:NRT、非ニコチン系薬物療法、処方薬、OTC薬 Global Smoking Cessation Drugs Market Forecast 2017-2027: NRT, Non-nicotine Pharmacotherapy, Prescription Drugs, OTC Drugs
出版日: 2017年10月31日 ページ情報: 英文 280 Pages
概要

世界の禁煙補助薬市場は、2017年〜2022年のCAGR (複合年間成長率) で、14.9%の成長が予測されています。

当レポートでは、世界の禁煙補助薬市場について調査分析し、主要促進要因と課題、収益予測、定性分析など、体系的な情報を提供しています。

第1章 レポート概要

第2章 禁煙のイントロダクション

  • 喫煙とは
  • ニコチン送達システムの種類とは
  • 喫煙の疫学
  • 人道/経済的負担
  • 喫煙:予防と治療

第3章 世界の禁煙補助薬市場のイントロダクション

  • 市場の定義・範囲
  • 世界の禁煙補助薬市場
  • 世界の市場区分:薬剤分類別
  • 世界の市場区分:地域別
  • 世界の市場区分:国別
  • 地域別の市場区分:薬剤分類別
  • 世界の禁煙補助薬市場全体の促進要因・抑制要因・動向

第4章 禁煙の研究・開発

  • パイプライン薬の作用機序
  • 進行中のパイプライン分子
  • 中止された分子

第5章 価格設定と償還の概要

  • オーストラリア
  • ニュージーランド
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 米国

第6章 禁煙療法とニコチン置換療法 (NRT) の市場概要:地域別

  • 米国
  • 英国
  • スペイン
  • フランス
  • オーストラリア
  • ニュージーランド
  • イタリア
  • ドイツ

第7章 世界の禁煙補助薬市場の定性分析

  • SWOT分析
  • 主要企業
    • Pfizer
    • GSK
    • J&J

第8章 結論

付録

目次
Product Code: PHA0254

The global smoking cessation drugs market is expected to grow at a CAGR of 14.9% in the first half of the forecast period. In 2016, the non-nicotine pharmacotherapy submarket held 56.2% of the global smoking cessation drugs market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 280-page report you will receive 175 tables and 150 figures- all unavailable elsewhere.

The 280-page report provides clear detailed insight into the global smoking cessation drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Smoking Cessation Drugs market forecasts from 2017-2027
  • This report also breaks down the revenue forecast for the global smoking cessation drugs market by type of therapy:
    • NRT
    • Non-Nicotine Pharmacotherapy
  • This report also breaks down the revenue forecast for the global smoking cessation drugs market by prescription vs OTC:
    • Prescription drugs
    • OTC
  • This report provides individual revenue forecasts to 2027 for these regions:
    • North America
    • Europe
    • Asia-Pacific
    • RoW

Each region is further segmented by type of therapy.

image1

  • This report provides the following qualitative analysis:
    • Epidemiology by geography, available treatment options, along with humanistic and economic burden
    • A SWOT Analysis
    • Pipeline molecules which are under development for the treatment of smoking cessation and detailed analysis on promising drug candidates
    • Pricing and reimbursement overview of the smoking cessation drugs market.
    • Leading companies that are the major players in the global smoking cessation drugs industry, including Pfizer, GlaxoSmithKline and Johnson & Johnson.

Visiongain's study is intended for anyone requiring commercial analyses for the global smoking cessation drugs market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Why You Should Read This Report
  • 1.2 How This Report Delivers
  • 1.3 Key Questions Answered by This Analytical Report Include:
  • 1.4 Who is This Report For?
  • 1.5 Methodology
    • 1.5.1 Primary Research
    • 1.5.2 Secondary Research
    • 1.5.3 Market Evaluation & Forecasting Methodology
  • 1.6 Frequently Asked Questions (FAQ)
  • 1.7 Associated visiongain Reports
  • 1.8 About visiongain

2. Introduction to Smoking Cessation

  • 2.1 What is Smoking?
    • 2.1.1 Types of Tobacco Smoking
  • 2.2 What are the various types of nicotine delivery systems?
  • 2.3 Epidemiology of Smoking
    • 2.3.1 Historical and Forecasted Prevalence of Current Tobacco Smoking in WHO Regions
    • 2.3.2 Prevalence of Tobacco Smoking in the Major Markets
      • 2.3.2.1 US
      • 2.3.2.2 Australia
      • 2.3.2.3 New Zealand
      • 2.3.2.4 Italy
      • 2.3.2.5 Germany
      • 2.3.2.6 Spain
      • 2.3.2.7 France
      • 2.3.2.8 UK
  • 2.4 Humanistic and Economic Burden
    • 2.4.1 Mortality
    • 2.4.2 Years Lost due to Disability (YLD)
    • 2.4.3 Labour-years Lost (LYL)
    • 2.4.4 Economic Impact
  • 2.5 Smoking: Prevention and Treatment
    • 2.5.1 Prevention
    • 2.5.2 Treatment

3. Introduction to the Global Smoking Cessation Drugs Market

  • 3.1 Market Definition and Scope
  • 3.2 Global Smoking Cessation Drugs Market 2016
    • 3.2.1 Global Smoking Cessation Drugs Market Forecast 2017-2027
  • 3.3 Global Market Segmentation by Drug Class
    • 3.3.1 Market Forecast by Drug Class, 2016-2027
  • 3.4 Global Market Segmentation by Region
    • 3.4.1 Market Forecast by Region, 2016-2027
      • 3.4.1.1 North America
      • 3.4.1.2 Europe
      • 3.4.1.3 Asia-Pacific (Japan, Australia, and New Zealand)
      • 3.4.1.4 RoW (Emerging Markets)
  • 3.5 Global Market Segmentation by Country
  • 3.6 Regional Market Segmentation by Drug Class, 2016-2027
    • 3.6.1 North America
    • 3.6.2 Europe
    • 3.6.3 Asia-Pacific (Japan, Australia, and New Zealand)
    • 3.6.4 Rest of the World (Emerging Markets)
  • 3.7 Overall Global Smoking Cessation Drugs Market Drivers, Restraints and Trends

4. Research and Development for Treating Smoking Cessation

  • 4.1 Novel Mechanism of Action of Pipeline Drugs
  • 4.2 Active Pipeline Molecules
    • 4.2.1 X-22
    • 4.2.2 CQSS 2 (Chrono Quit Smoking Solution 2) System
    • 4.2.3 CERC-501
    • 4.2.4 SEL-070 (SELA-070)
    • 4.2.5 EMB-001
    • 4.2.6 CVSI-007
  • 4.3 Discontinued Molecules
    • 4.3.1 NicVax
    • 4.3.2 SSR591813 (Dianicline)
    • 4.3.3 SR141716 (Rimonabant)
    • 4.3.4 TA-NIC
    • 4.3.5 Nic-002
    • 4.3.6 MK-0364 (Taranabant)
    • 4.3.7 SR147778 (Surinabant)
    • 4.3.8 APD356 (lorcaserin)
    • 4.3.9 GW468816
    • 4.3.10 EVP-6124
    • 4.3.11 GSK598809
    • 4.3.12 PF-05402536 (NIC7-001) and PF-06413367 (NIC7-003)

5. Pricing and Reimbursement Overview

  • 5.1 Australia
  • 5.2 New Zealand
  • 5.3 Germany
  • 5.4 France
  • 5.5 Italy
  • 5.6 Spain
  • 5.7 UK
  • 5.8 US

6. Smoking Cessation Therapies and NRT Market Overview, by Geography

  • 6.1 US
  • 6.2 UK
  • 6.3 Spain
  • 6.4 France
  • 6.5 Australia
  • 6.6 New Zealand
  • 6.7 Italy
  • 6.8 Germany

7. Qualitative Analysis of the Global Smoking Cessation Drugs Market

  • 7.1 SWOT Analysis, 2016
  • 7.2 Leading Companies in Global Smoking Cessation Drugs Market, 2016
    • 7.2.1 Pfizer
    • 7.2.2 GSK
    • 7.2.3 J&J

8. Conclusions

Appendices

  • Glossary
  • Associated visiongain Reports
  • Visiongain Report Sales Order Form
  • About visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1 Age-standardized Prevalence of Tobacco Smoking in People Aged 15 Years and More, by WHO Region, 2015
  • Table 2.2 WHO Definitions for Smoking Status
  • Table 2.3 Prevalence (%) of Current Tobacco Smoking in WHO Regions by Gender, 2010 and 2025
  • Table 2.4 List of Countries with >= 25% of Current Tobacco Smoking, in People Aged 15 Years and Above, 2015
  • Table 2.5 List of Countries with >= 25% of Daily Tobacco Smoking, in People Aged 15 Years and Above, 2015
  • Table 2.6 Crude Prevalence (%)of Current Tobacco Smoking in Key Geographies by Gender, 2010 and 2025
  • Table 2.7 Crude Prevalence (%) of Daily Tobacco Smoking in Key Geographies by Gender, 2010 and 2025
  • Table 2.8 Crude Prevalence (%) of Current Cigarette Smoking in Key Geographies by Gender, 2010 and 2025
  • Table 2.9 Crude Prevalence (%) of Daily Cigarette Smoking in Key Geographies by Gender, 2010 and 2025
  • Table 2.10 Prevalence (%) of Age-standardized Tobacco Smoking in People Aged 15 Years and More, 2015
  • Table 2.11 Key Tobacco and Smoking Related Surveys Conducted and/or Supported by the Office on Smoking and Health, US
  • Table 2.12 Prevalence (%)of Current Cigarette Smoking Among High School Students and Adults in the US, 1965-2014
  • Table 2.13 Prevalence (%) of Using Tobacco Products in Middle and High School Students by Product in the US, 2016
  • Table 2.14 Prevalence (%) of Using Tobacco Products in Middle and High School Students by Product in the US, 2015
  • Table 2.15 Percent of Students Who Report Smoking Cigarettes Daily in the US, by grade, 1976-2015
  • Table 2.16 Percent of Students who Reported Using Smokeless Tobacco in the US in the Last 30 Days, by grade, 1993-2015
  • Table 2.17 Prevalence of Any Tobacco Use of Any Tobacco Product among Adults Aged 18 Years and Over, by Gender and Age Group, US, 2009-2014
  • Table 2.18 Prevalence of Current Cigarette Smoking among Adults Aged 18 Years and Over, by Gender and Year, US, 1991-2015
  • Table 2.19 Prevalence of Current Cigarette Smoking among Males aged 18 Years and Over, by Age Group and Year, US, 1965-2014
  • Table 2.20 Prevalence of Current Cigarette Smoking among Females aged 18 Years and Over, by Age Group and Year, US, 1965-2014
  • Table 2.21 Prevalence of Current Cigarette Smoking among Adults aged 18 Years and Over, by Age Group, Gender, and Smoking Status, US, 2013-2015
  • Table 2.22 Prevalence (%) of Daily Tobacco Smoking by Gender, US, 2010, 2025 and 2030
  • Table 2.23 Prevalence (%) of Current Tobacco Smoking by Gender, US, 2010, 2025 and 2030
  • Table 2.24 Tobacco Smoking among People aged 14 Years and Over, by Smoking Status, Australia, 1991-2015 (%)
  • Table 2.25 Distribution of Tobacco Smoking Status among People aged 12 Years and Over, by Age Group and Gender, Australia, 2016
  • Table 2.26 Distribution of Tobacco Smoking Status among People aged 12 Years and Over, by Age Group and Gender, Australia, 2016
  • Table 2.27 Number of Smokers (in thousands), by Smoking Status, Age Group and Gender, Australia, 2014-2015
  • Table 2.28 Five-year Prevalence (%) of Current Tobacco Smoking in Australia, by Gender, 2000-2030
  • Table 2.29 Prevalence (%) of Current Tobacco Smoking in Australia, by Age, 2000-2030
  • Table 2.30 Prevalence (%) of Current Tobacco Smoking in Australia, by Age and Gender, 2000-2030
  • Table 2.31 Five-year Prevalence (%) of Daily Tobacco Smoking in Australia, by Gender, 2000-2030
  • Table 2.32 Definitions for Smoking Status Used in New Zealand Health Survey
  • Table 2.33 Prevalence(%) of Current Tobacco Smoking in New Zealand, by Gender, 2006-2016
  • Table 2.34 Prevalence (%) of Current Tobacco Smoking in New Zealand, by Age Group, 2006-2016
  • Table 2.35 Prevalence (%) of Current Tobacco Smoking in New Zealand, by Age Group and Gender, 2015/2016
  • Table 2.36 Prevalence (%) of Daily Tobacco Smoking in New Zealand, by Gender, 2006-2016
  • Table 2.37 Prevalence(%) of Daily Tobacco Smoking in New Zealand, by Age Group, 2006-2016
  • Table 2.38 Prevalence (%) of Daily Tobacco Smoking in New Zealand, by Age Group and Gender, 2015/2016
  • Table 2.39 Prevalence (%) of Current Tobacco Smoking in New Zealand, 1983-2015 Year
  • Table 2.40 Five-year Prevalence (%) of Daily Tobacco Smoking in New Zealand, by Gender, 2000-2030
  • Table 2.41 Five-year Prevalence (%) of Current Tobacco Smoking in New Zealand, by Gender, 2000-2030
  • Table 2.42 Prevalence (in thousands) of Smoking in People Aged 14 Years and Above, by Smoking Status, Italy, 2016
  • Table 2.43 Prevalence (in %) of Smoking in People Aged 14 Years and Above, by Gender, Italy, 2007-2016
  • Table 2.44 Prevalence (in thousands) of Smoking in People Aged 14 Years and Above, by Smoking Status, Italy, 2007-2016
  • Table 2.45 Prevalence (in %) of Smoking in People Aged 14 Years and Above, by Smoking Status, Italy, 2007-2016
  • Table 2.46 Prevalence (in %) of Smoking in Males Aged 14 Years and Above, by Smoking Status, Italy, 2007-2016
  • Table 2.47 Prevalence (in %) of Smoking in Females Aged 14 Years and Above, by Smoking Status, Italy, 2007-2016
  • Table 2.48 Prevalence (in %) of Smoking in People Aged 14 Years and Above, by Age , Italy, 2007-2016
  • Table 2.49 Prevalence (in thousands) of Smoking in People Aged 14 Years and Above, by Smoking Status and Age, Italy, 2001-2003 and 2005-2016
  • Table 2.50 Five-year Prevalence (%) of Current Tobacco Smoking in Italy, by Gender, 2000-2030
  • Table 2.51 Prevalence (%) of Current Tobacco Smoking in Italy, by Age, 2000-2030
  • Table 2.52 Prevalence (%) of Current Tobacco Smoking in Italy, by Age and Gender, 2000-2030
  • Table 2.53 Five-year Prevalence (%) of Daily Tobacco Smoking in Italy, by Gender, 2000-2030
  • Table 2.55 Definitions for Smoking Status used by Federal Health Reporting System
  • Table 2.56 Surveys Used to Determine Smoking Behavior by Federal Health Reporting System, Germany
  • Table 2.57 Prevalence (%) of Smoking in People aged 18 Years and Above, by Gender, Germany, 2009-2014/2015
  • Table 2.58 Prevalence (%) of Smoking in People aged 18 Years and Above, by Age and Gender, Germany, 2009-2014/2015
  • Table 2.59 Prevalence (%) of Smoking in Females aged 18 Years and Above, by Age and Smoking Status, Germany, 2014/2015
  • Table 2.60 Prevalence (%) of Smoking in Males aged 18 Years and Above, by Age and Smoking Status, Germany, 2014/2015
  • Table 2.61 Prevalence (%) of Smoking in Females aged 18 Years and Above, by Age and Smoking Status, Germany, 2010
  • Table 2.62 Prevalence (%) of Smoking in Males aged 18 Years and Above, by Age and Smoking Status, Germany, 2010
  • Table 2.63 Prevalence (%) of Smoking in Females aged 18 Years and Above, by Age and Smoking Status, Germany, 2009
  • Table 2.64 Prevalence (%) of Smoking in Males aged 18 Years and Above, by Age and Smoking Status, Germany, 2009
  • Table 2.65 Prevalence (%) of Smoking in People Aged 15 Years and Above, by Smoking Status and Gender, Germany, 1992-2013
  • Table 2.66 Prevalence (%) of Smoking in People Aged 15 Years and Above, by Age and Gender, Germany, 1992-2013
  • Table 2.67 Five-year Prevalence (%) of Current Tobacco Smoking in Germany, by Gender, 2000-2030
  • Table 2.68 Prevalence(%) of Current Tobacco Smoking in Germany, by Age, 2000-2030
  • Table 2.69 Prevalence(%) of Current Tobacco Smoking in Germany, by Age and Gender, 2000-2030
  • Table 2.70 Five-year Prevalence(%) of Daily Tobacco Smoking in Germany, by Gender, 2000-2030
  • Table 2.71 Relative Prevalence(%) of Tobacco Smoking in Population Aged 15 Years and Above, by Gender and Smoking Status, in Spain, 2014
  • Table 2.72 Relative Prevalence(%) of Tobacco Smoking in Population Aged 15 Years and Above, by Age and Smoking Status, in Spain, 2014
  • Table 2.73 Prevalence(%) of Tobacco Smoking in Population Aged 15 Years and Above, by Gender, Age, and Smoking Status, in Spain, 2014
  • Table 2.74 Number of Current Tobacco Smokers Aged 15 Years and Above - Daily and Occasional (in thousands), by Gender, in Spain, 2011-2012
  • Table 2.75 Number of Tobacco Smokers (in thousands) Aged 15 Years and Above, by Gender and Smoking Status, in Spain, 2011-2012
  • Table 2.76 Number of Tobacco Smokers (in thousands) Aged 15 Years and Above, by Age and Smoking Status, in Spain, 2011-2012
  • Table 2.77 Prevalence (%) of Tobacco Smoking, by Gender, Age, and Smoking Status in People Aged 15 Years and Above, in Spain, 2011-2012
  • Table 2.78 Relative Prevalence of Daily Tobacco Smoking (%) in People Aged 15 Years and Above, by Age and Gender, in Spain, 1993-2014
  • Table 2.79 Relative Prevalence of Daily Tobacco Smoking (%) in People Aged 15 Years and Above, by Age and Gender, in Spain, 1993-2014
  • Table 2.80 Relative Prevalence of Current Tobacco Smoking (%) in People Aged 15 Years and Above, by Age and Gender, in Spain, 1993-2014
  • Table 2.81 Relative Prevalence of Current Tobacco Smoking (%) in People Aged 15 Years and Above, by Age and Gender, in Spain, 1993-2014
  • Table 2.82 Five-year Prevalence (%) of Current Tobacco Smoking in Spain, by Gender, 2000-2030
  • Table 2.83 Prevalence (%) of Current Tobacco Smoking in Spain, by Age, 2000-2030
  • Table 2.84 Prevalence (%) of Current Tobacco Smoking in Spain, by Age and Gender, 2000-2030
  • Table 2.85 Five-year Prevalence (%) of Daily Tobacco Smoking in Spain, by Gender, 2000-2030
  • Table 2.86 Distribution of Smoking Status (in %), in France, 2010 and 2014
  • Table 2.87 Prevalence (%) of Regular Smoking in Males Aged 15 Years and Above, by Age in France, 2005, 2010 and 2014
  • Table 2.88 Prevalence (%) of Regular Smoking in Females Aged 15 Years and Above, by Age in France, 2005, 2010 and 2014
  • Table 2.89 Five-year Prevalence (%) of Current Tobacco Smoking in France, by Gender, 2000-2030
  • Table 2.90 Prevalence (%) of Current Tobacco Smoking in France, by Age, 2000-2030
  • Table 2.91 Prevalence (%) of Current Tobacco Smoking in France, by Age and Gender, 2000-2030
  • Table 2.92 Five-year Prevalence (%) of Daily Tobacco Smoking in France, by Gender, 2000-2030
  • Table 2.93 Prevalence (%) of Current Tobacco Smoking in People Aged 18 Years and Above, in the UK, 2010-2016
  • Table 2.94 Prevalence (%) of Current Tobacco Smoking in People Aged 18 Years and Above, by Age, in the UK, 2010-2016
  • Table 2.95 Prevalence (%) of Current Tobacco Smoking in People Aged 16 Years and Above, by Gender, in the UK, 2010-2015
  • Table 2.96 Prevalence (%) of Current Tobacco Smoking in People Aged 16 Years and Above, by Age, in the UK, 2010-2015
  • Table 2.97 Prevalence (%) of Current Tobacco Smoking in Males Aged 16 Years and Above, by Age, in the UK, 2010-2015
  • Table 2.98 Prevalence (%) of Current Tobacco Smoking in Females Aged 16 Years and Above, by Age, in the UK, 2010-2015
  • Table 2.99 Prevalence (%) of Daily Tobacco Smoking in People Aged 16 Years and Above, by Gender, in the UK, 2010-2015
  • Table 2.100 Prevalence (%) of Daily Tobacco Smoking in People Aged 16 Years and Above, by Age, in the UK, 2010-2015
  • Table 2.101 Prevalence (%) of Daily Tobacco Smoking in Females Aged 16 Years and Above, by Age, in the UK, 2010-2015
  • Table 2.102 Prevalence (%) of Current Tobacco Smoking in Males Aged 16 Years and Above, by Age, in the UK, 2010-2015
  • Table 2.103 Prevalence (%) of Tobacco Smoking in, by Gender and Smoking Status, in the UK, 2010, 2025, and 2030
  • Table 2.104 Number of Smoking-related Deaths in the WHO Regions, All Ages, 2010
  • Table 2.105 Smoking-attributable Burden of Disease and LYL Among Adults aged 30-69 years, 2012
  • Table 2.106 Smoking-attributable Burden of Disease, by Geography, 2012
  • Table 2.107 Economic Cost of Smoking-attributable Diseases, 2012
  • Table 2.108 Economic Cost of Smoking-attributable Diseases, Adjusted for 2016 PPP
  • Table 3.1 Global Smoking Cessation Drugs Market by Segmentation, 2016
  • Table 3.2 Global Smoking Cessation Drugs Market Forecast 2017-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 3.3 Global Smoking Cessation Drugs Market Forecast by Drug Class 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 3.4 Global Smoking Cessation Drugs Market by Region, 2016
  • Table 3.5 Global Smoking Cessation Drugs Market Forecast by Region 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 3.6 Global Smoking Cessation Drugs Market by Country, 2016
  • Table 3.7 North American Smoking Cessation Drugs Market Segmentation by Drug Class 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 3.8 European Smoking Cessation Drugs Market Segmentation by Drug Class 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 3.9 APAC Smoking Cessation Drugs Market Segmentation by Drug Class 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 3.10 RoW Smoking Cessation Drugs Market Segmentation by Drug Class 2016-2027: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.1 Active Pipeline Molecules for Smoking Cessation, 2017
  • Table 4.2 Discontinued Pipeline Molecules for Smoking Cessation, 2017
  • Table 5.1 Status of Smoking Cessation Reimbursement in Australia, as of December 2016
  • Table 5.2 Status of Smoking Cessation Reimbursement in New Zealand, as of December 2016
  • Table 5.3 Status of Smoking Cessation Reimbursement in Germany, as of December 2016
  • Table 5.4 Status of Smoking Cessation Reimbursement in France, as of December 2016
  • Table 5.5 Status of Smoking Cessation Reimbursement in Italy, as of December 2016
  • Table 5.6 Status of Smoking Cessation Reimbursement in Spain, as of December 2016
  • Table 5.7 Status of Smoking Cessation Reimbursement in the UK, as of December 2016
  • Table 5.8 Status of Smoking Cessation Reimbursement in the US, as of December 2016
  • Table 6.1 Type of Smoking Cessation Therapies Approved in the US, 2017
  • Table 6.2 List of Smoking Cessation Drugs Approved in the US, 2017
  • Table 6.3 List of Smoking Cessation Drugs with Discontinued/Tentative Approval Marketing Status in the US, 2017
  • Table 6.4 NRT Market in the US
  • Table 6.5 NRT Market Leaders for Traditional Product Categories in the US, 2016
  • Table 6.6 Nicotine Gums Market in the US
  • Table 6.7 Nicotine Lozenges Market in the US
  • Table 6.8 Nicotine Patch Market in the US
  • Table 6.9 Non-Nicotine Smoking Cessation Pharmacotherapy Market in the US
  • Table 6.10 Usage of Any Smoking Cessation Method (Alone or in Combination) in the US, in Past 3 Months, 2014-2016
  • Table 6.11 Usage of Only One Smoking Cessation Method (Alone or in Combination) in the US, in Past 3 Months, 2014-2016
  • Table 6.12 Type of Smoking Cessation Therapies Approved in the UK, 2017
  • Table 6.13 List of Smoking Cessation Drugs Approved in the UK, 2017
  • Table 6.14 List of Smoking Cessation Drugs with Discontinued Marketing Status in the UK, 2017
  • Table 6.15 NRT Market in the UK
  • Table 6.16 Nicotine Gums Market in the UK
  • Table 6.17 Nicotine Lozenges Market in the UK
  • Table 6.18 Nicotine Patches Market in the UK
  • Table 6.19 Non-Nicotine Smoking Cessation Pharmacotherapy Market in the UK
  • Table 6.20 Number of Prescriptions (in thousands) of Smoking Cessation Drugs Prescribed in Primary Care, in England, 2004/05 to 2014/15
  • Table 6.21 Net Ingredient Cost of Smoking Cessation Drugs Prescribed in Primary Care, in England, 2004/05 to 2014/15
  • Table 6.22 Type of Smoking Cessation Therapies Approved in Spain, 2017
  • Table 6.23 List of Smoking Cessation Drugs Approved in Spain, 2017
  • Table 6.24 List of Smoking Cessation Drugs with Discontinued Marketing Status in Spain, 2017
  • Table 6.25 NRT Market in Spain
  • Table 6.26 Type of Smoking Cessation Therapies Approved in France, 2017
  • Table 6.27 List of Smoking Cessation Drugs Approved in France, 2017
  • Table 6.28 NRT Market in France, 2017
  • Table 6.29 Type of Smoking Cessation Therapies Approved in Australia, 2017
  • Table 6.30 List of Smoking Cessation Drugs Approved in Australia, 2017
  • Table 6.31 NRT Market in Australia
  • Table 6.32 Type of Smoking Cessation Therapies Approved in New Zealand, 2017
  • Table 6.33 List of Smoking Cessation Drugs Approved in New Zealand, 2017
  • Table 6.34 List of Smoking Cessation Drugs with Lapsed Approval in New Zealand, 2017
  • Table 6.35 List of Smoking Cessation Drugs with Status 'Not Available' in New Zealand, 2017
  • Table 6.36 NRT Market in New Zealand
  • Table 6.37 Type of Smoking Cessation Therapies Approved in Italy, 2017
  • Table 6.38 List of Smoking Cessation Drugs Approved in Italy, 2017
  • Table 6.39 List of Smoking Cessation Drugs with status 'Revoked' in Italy, 2017
  • Table 6.40 NRT Market in Italy
  • Table 6.41 NRT Market in Germany
  • Table 7.1 Global Smoking Cessation Market Leaders, 2016
  • Table 7.2 Sales (in US$ Million) of Chantix/Champix
  • Table 7.3 Chantix: Exclusivity and Patent Expiry Status in the US
  • Table 7.4 Sales of Perrigo's Smoking Cessation Products
  • Table 8.1 Age-standardized Prevalence of Tobacco Smoking in People Aged 15 Years and More, by WHO Region, 2015
  • Table 8.2 Prevalence (%) of Current Tobacco Smoking in WHO Regions by Gender, 2010 and 2025

List of Figures

  • Figure 2.1 Types of Nicotine Delivery Systems
  • Figure 2.2 Prevalence (%) of Current Tobacco Smoking in WHO Regions, 2010 and 2025
  • Figure 2.3 Trend of Current Cigarette Smoking Among High School Students and Adults in the US, 1965-2014
  • Figure 2.4 Trend of Current Cigarette Smoking Among High School Students in the US, 2011-2016
  • Figure 2.5 Trend of Current Cigarette Smoking Among Middle School Students in the US, 2011-2016
  • Figure 2.6 Trend of Daily Cigarette Smoking in the US, by Grade, 1976-2015
  • Figure 2.7 Trend of Students who Reported Using Smokeless Tobacco in the US in the Last 30 Days, by Grade, 1993-2015
  • Figure 2.8 Trend of Current Cigarette Smoking among Adults Aged 18 Years and Over in the US, by Gender and Year, 1991-2015
  • Figure 2.9 Age Group-wise Prevalence of Current Cigarette Smoking among Males aged 18 Years and Over in the US, by Year, 1965-2014
  • Figure 2.10 Year-wise Prevalence of Current Cigarette Smoking among Males aged 18 Years and Over in the US, by Age Group, 1965-2014
  • Figure 2.11 Age Group-wise Prevalence of Current Cigarette Smoking among Females Aged 18 Years and Over in the US, by Year, 1965-2014
  • Figure 2.12 Year-wise Prevalence of Current Cigarette Smoking among Females aged 18 Years and Over in the US, by Age Group, 1965-2014
  • Figure 2.13 Prevalence of Current Cigarette Smoking among Adults aged 18 Years and Over, by Smoking Status, US, 2013-2015
  • Figure 2.14 Trend in Prevalence of Current Cigarette Smoking among Adults aged 18 Years and Over, by Smoking Status, US, 2013-2015
  • Figure 2.15 Prevalence (%) of Daily Tobacco Smoking by Gender, US, 2010, 2025 and 2030
  • Figure 2.16 Prevalence (%) of Current Tobacco Smoking by Gender, US, 2010, 2025 and 2030
  • Figure 2.17 Trend in Prevalence of Tobacco Smoking among People aged 14 Years and Over, by Smoking Status, Australia, 1991-2015
  • Figure 2.18 Year-wise Distribution (in %) of Tobacco Smoking Status in Australia in People Aged 14 Years and Above, 1991-2016
  • Figure 2.19 Trend in Year-wise Distribution of Tobacco Smoking Status in Australia in People Aged 14 Years and Above, 1991-2016 (%)
  • Figure 2.20 Year-wise Distribution (in %) of Tobacco Smoking Status in Australia in People Aged 12 Years and Above, 2016
  • Figure 2.21 Trend in Year-wise Distribution of Daily Smokers in Australia, by Age Group, 1991-2016 (%)
  • Figure 2.22 Trend in Year-wise Distribution of Current Smokers in Australia, by Age Group, 1991-2016 (%)
  • Figure 2.23 Prevalence (in thousands) of Smoking in Australia, by Age Group, 2014-2015
  • Figure 2.24 Prevalence (in thousands) of Smoking in Australia, by Age Group and Gender, 2014-2015
  • Figure 2.25 Distribution (in %) of Tobacco Smoker in Australia, by Age Group and Smoking Status, 2014-2015
  • Figure 2.26 Five-year Prevalence (%) of Current Tobacco Smoking in Australia, by Gender, 2000-2030
  • Figure 2.27 Five-year Prevalence(%) of Current Tobacco Smoking in Australia, 2000-2030
  • Figure 2.28 Trend of Current Tobacco Smoking in Australia, by Age, 2000-2030
  • Figure 2.29 Five-year Prevalence(%) of Daily Tobacco Smoking in Australia, by Gender, 2000-2030
  • Figure 2.30 Five-year Prevalence(%) of Daily Tobacco Smoking in Australia, 2000-2030
  • Figure 2.31 Prevalence(%) of Current Tobacco Smoking in New Zealand, by Gender, 2006-2016
  • Figure 2.32 Prevalence(%) of Current Tobacco Smoking in New Zealand, by Age Group, 2006-2016
  • Figure 2.33 Trend in Prevalence (%) of Current Tobacco Smoking in New Zealand, by Age Group, 2006-2016
  • Figure 2.34 Prevalence(%) of Current Tobacco Smoking in New Zealand, by Age Group, 2006-2016
  • Figure 2.35 Prevalence(%) of Daily Tobacco Smoking in New Zealand, by Gender, 2006-2016
  • Figure 2.36 Prevalence(%) of Daily Tobacco Smoking in New Zealand, by Age Group, 2006-2016
  • Figure 2.37 Trend in Prevalence(%) of Daily Tobacco Smoking in New Zealand, by Age Group, 2006-2016
  • Figure 2.38 Prevalence (%) of Daily Tobacco Smoking in New Zealand, by Age Group, 2006-2016
  • Figure 2.39 Trend of Prevalence(%) of Current Tobacco Smoking in New Zealand, 1983-2015
  • Figure 2.40 Five-year Prevalence (%) of Daily Tobacco Smoking in New Zealand, by Gender, 2000-2030
  • Figure 2.41 Five-year Prevalence(%) of Daily Tobacco Smoking in New Zealand, 2000-2030
  • Figure 2.42 Five-year Forecasted Prevalence(%) of Current Tobacco Smoking in New Zealand, by Gender, 2000-2030
  • Figure 2.43 Five-year Prevalence(%) of Current Tobacco Smoking in New Zealand, 2000-2030
  • Figure 2.44 Prevalence (in thousands) of Smoking in People Aged 14 Years and Above, by Smoking Status, Italy, 2016
  • Figure 2.45 Trend in Prevalence (in %) of Smoking in People Aged 14 Years and Above, by Gender, Italy, 2007-2016
  • Figure 2.46 Prevalence (in thousands) of Smoking in People Aged 14 Years and Above, by Smoking Status, Italy, 2007-2016
  • Figure 2.47 Trend in Prevalence (in %) of Smoking in People Aged 14 Years and Above, by Smoking Status, Italy, 2007-2016
  • Figure 2.48 Trend in Prevalence (in %) of Smoking in Males Aged 14 Years and Above, by Smoking Status, Italy, 2007-2016
  • Figure 2.49 Trend in Prevalence (in %) of Smoking in Females Aged 14 Years and Above, by Smoking Status, Italy, 2007-2016
  • Figure 2.50 Prevalence (in %) of Smoking in People Aged 14 Years and Above, by Age, Italy, 2007-2016
  • Figure 2.51 Trend in Prevalence (in %) of Smoking in People Aged 14 Years and Above, by Age, Italy, 2007-2016
  • Figure 2.52 Five-year Prevalence(%) of Current Tobacco Smoking in Italy, by Gender, 2000-2030
  • Figure 2.53 Five-year Prevalence(%) of Current Tobacco Smoking in Italy, by Gender, 2000-2030
  • Figure 2.54 Trend of Current Tobacco Smoking in Italy, by Age, 2000-2030
  • Figure 2.55 Five-year Prevalence(%) of Daily Tobacco Smoking in Italy, by Gender, 2000-2030
  • Figure 2.56 Five-year Prevalence (%) of Daily Tobacco Smoking in Italy, 2000-2030
  • Figure 2.57 Trend in Prevalence (%) of Smoking in People aged 18 Years and Above, by Gender, Germany, 2009-2014/2015
  • Figure 2.58 Trend in Prevalence(%) of Smoking in People aged 18 Years and Above, Germany, 2009-2014/2015
  • Figure 2.59 Trend in Prevalence(%) of Smoking in People aged 18 Years and Above, by Age and Gender, Germany, 2009-2014/2015
  • Figure 2.60 Prevalence(%) of Smoking in Females aged 18 Years and Above, by Age and Smoking Status, Germany, 2014/2015
  • Figure 2.61 Prevalence (%) of Smoking in Males aged 18 Years and Above, by Age and Smoking Status, Germany, 2014/2015
  • Figure 2.62 Prevalence (%) of Smoking in Females aged 18 Years and Above, by Age and Smoking Status, Germany, 2010
  • Figure 2.63 Prevalence (%) of Smoking in Males aged 18 Years and Above, by Age and Smoking Status, Germany, 2010
  • Figure 2.64 Prevalence (%) of Smoking in Females aged 18 Years and Above, by Age and Smoking Status, Germany, 2009
  • Figure 2.65 Prevalence (%) of Smoking in Males aged 18 Years and Above, by Age and Smoking Status, Germany, 2009
  • Figure 2.66 Trend in Prevalence(%) of Smoking in People aged 15 Years and Above, by Gender and Smoking Status, Germany, 1992-2013
  • Figure 2.67 Five-year Prevalence(%) of Current Tobacco Smoking in Italy, by Gender, 2000-2030
  • Figure 2.68 Five-year Prevalence(%) of Current Tobacco Smoking in Germany, 2000-2030
  • Figure 2.69 Trend of Current Tobacco Smoking in Germany, by Age, 2000-2030
  • Figure 2.70 Five-year Prevalence(%) of Daily Tobacco Smoking in Germany, 2000-2030
  • Figure 2.71 Five-year Prevalence(%) of Daily Tobacco Smoking in Germany, 2000-2030
  • Figure 2.72 Relative Prevalence(%) of Tobacco Smoking in Population Aged 15 Years and Above, by Gender and Smoking Status, in Spain, 2014
  • Figure 2.73 Relative Prevalence (%) of Tobacco Smoking in Population Aged 15 Years and Above, by Age and Smoking Status, in Spain, 2014
  • Figure 2.74 Number of Tobacco Smokers (in thousands), by Gender and Smoking Status, in Spain, 2011-2012
  • Figure 2.75 Number of Tobacco Smokers (in thousands) Aged 15 Years and Above, by Age and Smoking Status, in Spain, 2011-2012
  • Figure 2.76 Relative Prevalence of Daily Tobacco Smoking (%) in People Aged 15 Years and Above, by Gender, in Spain, 1993-2014
  • Figure 2.77 Trend in Relative Prevalence of Tobacco Smokers (%) in Spain, by Gender, 2011-2012
  • Figure 2.78 Relative Prevalence of Current Tobacco Smoking (%) in People Aged 15 Years and Above, by Age Gender, in Spain, 1993-2014
  • Figure 2.79 Trend in Relative Prevalence of Current Tobacco Smokers (%) in Spain, by Gender, 2011-2012
  • Figure 2.80 Five-year Prevalence(%) of Current Tobacco Smoking in Spain, by Gender, 2000-2030
  • Figure 2.81 Five-year Prevalence (%) of Current Tobacco Smoking in Spain, 2000-2030
  • Figure 2.82 Trend of Current Tobacco Smoking in Spain, by Age, 2000-2030
  • Figure 2.83 Five-year Prevalence(%) of Daily Tobacco Smoking in Spain, by Gender, 2000-2030
  • Figure 2.84 Five-year Prevalence(%) of Daily Tobacco Smoking in Spain, 2000-2030
  • Figure 2.85 Distribution of Smoking Status, in France, 2010 and 2014
  • Figure 2.86 Trend in Distribution of Smoking Status, in France, 2010 and 2014
  • Figure 2.87 Prevalence (%) of Regular Smoking in Males Aged 15 Years and Above, by Age in France, 2005, 2010 and 2014
  • Figure 2.88 Trend in Prevalence (%) of Regular Smoking in Males Aged 15 Years and Above, by Age in France, 2005, 2010 and 2014
  • Figure 2.89 Prevalence (%) of Regular Smoking in Females Aged 15 Years and Above, by Age in France, 2005, 2010 and 2014
  • Figure 2.90 Trend in Prevalence (%) of Regular Smoking in Females Aged 15 Years and Above, by Age in France, 2005, 2010 and 2014
  • Figure 2.91 Five-year Prevalence(%) of Current Tobacco Smoking in France, by Gender, 2000-2030
  • Figure 2.92 Five-year Prevalence(%) of Current Tobacco Smoking in France, 2000-2030
  • Figure 2.93 Trend of Current Tobacco Smoking in France, by Age, 2000-2030
  • Figure 2.94 Five-year Prevalence(%) of Daily Tobacco Smoking in France, by Gender, 2000-2030
  • Figure 2.95 Five-year Prevalence (%) of Daily Tobacco Smoking in France, 2000-2030
  • Figure 2.96 Prevalence(%) of Current Tobacco Smoking in People Aged 18 Years and Above, in the UK, 2010-2016
  • Figure 2.97 Prevalence(%) of Current Tobacco Smoking in People Aged 18 Years and Above, by Age Group, in the UK, 2016
  • Figure 2.98 Prevalence(%) of Current Tobacco Smoking in People Aged 18 Years and Above, by Age Group, in the UK, 2010-2016
  • Figure 2.99 Trend in Prevalence(%) of Current Tobacco Smoking in People Aged 18 Years and Above, by Age Group, in the UK, 2010-2016
  • Figure 2.100 Prevalence(%) of Current Tobacco Smoking in People Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
  • Figure 2.101 Trend in Prevalence (%) of Current Tobacco Smoking in People Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
  • Figure 2.102 Prevalence(%) of Current Tobacco Smoking in People Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
  • Figure 2.103 Prevalence (%) of Current Tobacco Smoking in Males Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
  • Figure 2.104 Prevalence (%) of Current Tobacco Smoking in Females Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
  • Figure 2.105 Prevalence(%) of Daily Tobacco Smoking in People Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
  • Figure 2.106 Trend in Prevalence (%) of Daily Tobacco Smoking in People Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
  • Figure 2.107 Prevalence(%) of Daily Tobacco Smoking in People Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
  • Figure 2.108 Prevalence(%) of Daily Tobacco Smoking in Females Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
  • Figure 2.109 Prevalence(%) of Current Tobacco Smoking in Males Aged 16 Years and Above, by Age Group, in the UK, 2010-2015
  • Figure 2.110 Prevalence(%) of Tobacco Smoking in, by Gender and Smoking Status, in the UK, 2010, 2025, and 2030
  • Figure 2.111 Strategies to Prevent Smoking Initiation in Children and Adolescents
  • Figure 3.1 Global Smoking Cessation Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 3.2 Global Smoking Cessation Drugs Market Segmentation by Drug Class 2016: Share (%)
  • Figure 3.3 Global NRT Smoking Cessation Market Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 3.4 Global Non-nicotine Pharmacotherapy Smoking Cessation Market Forecast 2016-2027: Revenue ($m), AGR (%)
  • Figure 3.5 Global Smoking Cessation Drugs Market Forecast by Drug Class 2016-2027: Revenue ($m)
  • Figure 3.6 Trend in Global Smoking Cessation Drugs Market by Drug Class 2016-2027: Revenue ($m)
  • Figure 3.7 Global Smoking Cessation Drugs Market Segmentation by Drug Class 2027: Share (%)
  • Figure 3.8 Global Smoking Cessation Drugs Market by Region, 2016: Share (%)
  • Figure 3.9 Global Smoking Cessation Drugs Market by Region, 2027: Share (%)
  • Figure 3.10 Smoking Cessation Drugs Market Forecast 2016-2027, North America: Revenue ($m), AGR (%)
  • Figure 3.11 Smoking Cessation Drugs Market Forecast 2016-2027, Europe: Revenue ($m), AGR (%)
  • Figure 3.12 Smoking Cessation Drugs Market Forecast 2016-2027, Asia-Pacific: Revenue ($m), AGR (%)
  • Figure 3.13 Smoking Cessation Drugs Market Forecast 2016-2027, RoW: Revenue ($m), AGR (%)
  • Figure 3.14 Global Smoking Cessation Drugs Market by Country, 2016: Share (%)
  • Figure 3.15 NRT Smoking Cessation Market Forecast 2016-2027, North America: Revenue ($m), AGR (%)
  • Figure 3.16 Non-nicotine Pharmacotherapy Smoking Cessation Market Forecast 2016-2027, North America: Revenue ($m), AGR (%)
  • Figure 3.17 North American Smoking Cessation Drugs Market Forecast by Drug Class 2016-2027: Revenue ($m)
  • Figure 3.18 Trend in North American Smoking Cessation Drugs Market by Drug Class 2016-2027: Revenue ($m)
  • Figure 3.19 NRT Smoking Cessation Market Forecast 2016-2027, Europe: Revenue ($m), AGR (%)
  • Figure 3.20 Non-nicotine Pharmacotherapy Smoking Cessation Market Forecast 2016-2027, Europe: Revenue ($m), AGR (%)
  • Figure 3.21 European Smoking Cessation Drugs Market Forecast by Drug Class 2016-2027: Revenue ($m)
  • Figure 3.22 Trend in European Smoking Cessation Drugs Market by Drug Class 2016-2027: Revenue ($m)
  • Figure 3.23 NRT Smoking Cessation Market Forecast 2016-2027, APAC: Revenue ($m), AGR (%)
  • Figure 3.24 Non-nicotine Pharmacotherapy Smoking Cessation Market Forecast 2016-2027, APAC: Revenue ($m), AGR (%)
  • Figure 3.25 APAC Smoking Cessation Drugs Market Forecast by Drug Class 2016-2027: Revenue ($m)
  • Figure 3.26 Trend in APAC Smoking Cessation Drugs Market by Drug Class 2016-2027: Revenue ($m)
  • Figure 3.27 NRT Smoking Cessation Market Forecast 2016-2027, RoW: Revenue ($m), AGR (%)
  • Figure 3.28 Non-nicotine Pharmacotherapy Smoking Cessation Market Forecast 2016-2027, RoW: Revenue ($m), AGR (%)
  • Figure 3.29 RoW Smoking Cessation Drugs Market Forecast by Drug Class 2016-2027: Revenue ($m)
  • Figure 3.30 Trend in RoW Smoking Cessation Drugs Market Forecast by Drug Class 2016-2027: Revenue ($m)
  • Figure 3.31 Trends in Global Smoking Cessation Drugs Market
  • Figure 6.1 Usage of Any Smoking Cessation Method (Alone or in Combination) in the US, in Past 3 Months, 2014-2016*
  • Figure 6.2 Usage of Only One Smoking Cessation Method (Alone or in Combination) in the US, in Past 3 Months, 2014-2016*
  • Figure 6.3 Trend in Number of Prescriptions (in thousands) of Smoking Cessation Drugs Prescribed in Primary Care, in England, 2004/05 to 2014/15
  • Figure 6.4 Distribution of Net Ingredient Cost of Smoking Cessation Drugs Prescribed in Primary Care, in England, 2004/05 to 2014/15
  • Figure 6.5 Sales of Smoking Cessation Treatments in France, 1998-2016
  • Figure 7.1 Global Smoking Cessation Market Leaders by Market Share, 2016: Share (%)
  • Figure 8.1 Global Smoking Cessation Drugs Market Forecast 2017-2027: Revenue ($m), AGR (%)

Companies Listed

  • 22nd Century Group, Inc
  • Actavis (Teva)
  • AFT Pharmaceuticals
  • Alphapharm
  • Apotex
  • Aveva
  • Celtic Pharmaceuticals (earlier Xenova Group)
  • Cerecor Inc
  • Chefaro Pharma
  • Chrono Therapeutics
  • CV Sciences
  • Douglas Pharmaceuticals
  • Dr Reddys Labs
  • Eisai/Arena Pharmaceuticals
  • Embera NeuroTherapeutics
  • FDA
  • Forum Pharmaceuticals Mitsubishi Tanabe Pharma
  • Geiss, Destin & Dunn (GDD) Inc.
  • Gelmedic Holding
  • GSK
  • GSKSS
  • Ivax Sub Teva Pharms
  • Kern Pharma
  • McNeil (J&J)
  • Medis Pharma
  • Merck
  • Mylan
  • Nabi Pharmaceuticals (now Aviragen)/GSK
  • National Institute on Drug Abuse
  • Novartis
  • Novartis/Cytos Biotechnology (now Kuros BioSciences)
  • Office on Smoking and Health
  • Omega Pharma
  • Orion Laboratories (Perrigo)
  • Perrigo
  • Pfizer
  • Pharmacia and Upjohn (Pfizer)
  • Pharmacia Italia
  • Pierre Fabre
  • Pinney Associates
  • Recordati Chimica Industria E Farmaceutica
  • Reynolds America
  • Sanofi
  • Sanofi Aventis
  • Selecta Biosciences
  • Tarbis Farma
  • Teva
  • The Boots Company
  • University of Washington
  • Watson Labs (Teva)
  • WHO
  • Wrafton Laboratories (Perrigo)
Back to Top